Target type: molecularfunction
Catalysis of the addition of a second methyl group to methylated peptidyl-arginine. Methylation is on the terminal nitrogen (omega nitrogen) residue that is not already methylated, resulting in symmetrical peptidyl-N(omega),N'(omega)-dimethyled arginine residues. [EC:2.1.1.320, PMID:14705965, RESID:AA0067, RESID:AA0069]
Protein-arginine omega-N symmetric methyltransferase activity refers to the enzymatic process by which a methyl group is transferred from a donor molecule, typically S-adenosyl methionine (SAM), to the omega-nitrogen of an arginine residue within a protein. This methylation event occurs specifically at the terminal nitrogen atom of the guanidino group of arginine, resulting in the formation of monomethylarginine (MMA).
This activity is crucial for a variety of cellular processes, including:
* **Regulation of protein function:** Methylation of arginine residues can alter the structure and conformation of proteins, thereby influencing their activity. This can range from subtle changes in enzyme kinetics to complete inactivation or activation of a protein.
* **Signal transduction:** Methylated arginine residues can act as binding sites for other proteins, facilitating protein-protein interactions and mediating signal transduction pathways.
* **Chromatin remodeling:** Methylation of arginine residues within histone proteins, which package DNA into nucleosomes, plays a crucial role in regulating gene expression. Different methylation patterns can influence chromatin accessibility and the recruitment of specific transcription factors.
* **Cell signaling:** Methylation of arginine residues in various signaling proteins, including kinases and phosphatases, can modulate their activity and downstream signaling pathways.
The enzymes responsible for protein-arginine omega-N symmetric methyltransferase activity belong to a family of methyltransferases known as protein arginine methyltransferases (PRMTs). There are multiple PRMT isoforms, each with distinct substrate specificities and regulatory mechanisms. The different PRMTs generate various methylation products, including monomethylarginine (MMA), symmetric dimethylarginine (SDMA), and asymmetric dimethylarginine (ADMA), each contributing to specific cellular functions.
In summary, protein-arginine omega-N symmetric methyltransferase activity is a fundamental enzymatic process that plays a critical role in regulating various cellular functions through the specific methylation of arginine residues within proteins. This activity is essential for maintaining cellular homeostasis, coordinating signal transduction pathways, and regulating gene expression.'
"
Protein | Definition | Taxonomy |
---|---|---|
Protein arginine N-methyltransferase 5 | A protein arginine N-methyltransferase 5 that is encoded in the genome of human. [PRO:DNx, UniProtKB:O14744] | Homo sapiens (human) |
Protein arginine N-methyltransferase 7 | A protein arginine N-methyltransferase 7 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9NVM4] | Homo sapiens (human) |
Protein arginine N-methyltransferase 5 | A protein arginine N-methyltransferase 5 that is encoded in the genome of human. [PRO:DNx, UniProtKB:O14744] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
pentamidine | pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease. Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | aromatic ether; carboxamidine; diether | anti-inflammatory agent; antifungal agent; calmodulin antagonist; chemokine receptor 5 antagonist; EC 2.3.1.48 (histone acetyltransferase) inhibitor; NMDA receptor antagonist; S100 calcium-binding protein B inhibitor; trypanocidal drug; xenobiotic |
s-adenosylmethionine | acylcarnitine: structure in first source S-adenosyl-L-methioninate : A sulfonium betaine that is a conjugate base of S-adenosyl-L-methionine obtained by the deprotonation of the carboxy group. | sulfonium betaine | human metabolite |
hexamidine | hexamidine : A polyether that is the bis(4-guanidinophenyl) ether of hexane-1,6-diol. | aromatic ether; guanidines; polyether | antimicrobial agent; antiseptic drug |
sinefungin | adenosines; non-proteinogenic alpha-amino acid | antifungal agent; antimicrobial agent | |
furamidine | furamidine: RN given refers to parent cpd; WR 199385 refers to di-HCl; pafuramidine is a prodrug of this | ||
s-adenosylhomocysteine | S-adenosyl-L-homocysteine : An organic sulfide that is the S-adenosyl derivative of L-homocysteine. S-Adenosylhomocysteine: 5'-S-(3-Amino-3-carboxypropyl)-5'-thioadenosine. Formed from S-adenosylmethionine after transmethylation reactions. | adenosines; amino acid zwitterion; homocysteine derivative; homocysteines; organic sulfide | cofactor; EC 2.1.1.72 [site-specific DNA-methyltransferase (adenine-specific)] inhibitor; EC 2.1.1.79 (cyclopropane-fatty-acyl-phospholipid synthase) inhibitor; epitope; fundamental metabolite |
5'-methylthioadenosine | 5'-methylthioadenosine: structure 5'-S-methyl-5'-thioadenosine : Adenosine with the hydroxy group at C-5' substituted with a methylthio (methylsulfanyl) group. | thioadenosine | algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite |
stilbamidine | stilbamidine: RN given refers to parent cpd | ||
epz004777 | N-glycosyl compound | ||
gsk343 | GSK343 : A member of the class of indazoles that is 1-isopropyl-1H-indazole-4-carboxamide in which the nitrogen of the carboxamide group is substituted by a (6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl group and in which the indazole ring is substituted at position 6 by a 2-(4-methylpiperazin-1-yl)pyridin-4-yl group. A highly potent and selective EZH2 inhibitor (IC50 = 4 nM). GSK343: an EZH2 methyltransferase inhibitor | aminopyridine; indazoles; N-alkylpiperazine; N-arylpiperazine; pyridone; secondary carboxamide | antineoplastic agent; apoptosis inducer; EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor |
6,7-dimethoxy-2-(pyrrolidin-1-yl)-n-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine | 6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine: a SETD8 inhibitor; structure in first source | ||
gsk3235025 | GSK3235025: an inhibitor of protein arginine methyltransferase-5 (PRMT5); structure in first source |